Skip to main content
. Author manuscript; available in PMC: 2021 Feb 13.
Published in final edited form as: Nanomedicine. 2019 Mar 8;18:189–195. doi: 10.1016/j.nano.2019.02.021

Table 2.

Phase I Dose Cohorts and Dose Limiting Toxicity

CRLX101 Schedule Dose N DLT
Week 1, 3, 5 12 mg/m2 3 None
15 mg/m2 6 None
Weekly 12 mg/m2 3 None
15 mg/m2 6 1: Skin desquamation with 6 day treatment break